Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (5396)	9/25/1998 11:54:00 AM
From: margie	Read Replies (1) \| Respond to of 6136

CNN will be covering Agouron's presentation tomorrow, Compound Found to Reduce Replication of Common Cold Virus in Vitro. Session 87-H, Papers H-61 and H-62 (Slide sessions) asmusa.org for Paper H-61 available online. It is listed in the selected program highlights asmusa.org Agouron is excited about it. I think they expect to start Phase I in early 99 but I'm not sure. Agouron has synthesized HRV 3C protease inhibitors. During infection, there are elevated levels of IL-6 and IL-8 in the nasal passage, inflammatory cytokines. These inhibitors are being designed to inhibit the levels of both cytokines as well as infectious virus. This has implications for the development of anti-HRV agents to block replication and diminish symptoms. Agouron is presenting these two slide sessions, H-62 and H-61 Saturday 8:30 AM Note: This is for the common cold, not influenza or flu that Gilead and Glaxo are working on. Gilead and Glaxo are presenting Phase II/III data on their oral drugs to treat the influenza or the flu.. There is an article in the WSJ today about Gilead and Glaxo's progress. They are both in Phase II/III. Sorry, I can't finish this now. Agouron is presenting many abstracts, one on switching patients to Viracept from Crixivan. I wish that Dupont would present some results on how well patients do who switch to Sustiva from Crixivan or other protease inhibitors. I would think that Merck's discontinuation of Crixivan BID would have made some patients think twice before switching to a regimen that is based on very preliminary short term data. There is a lot of hype at these meetings, and data in many cases is preliminary, short term, and does not always hold up. Many patients were switched to Crixivan BID.